Dykema Arbor G, Vodusek Ziga, Karagenova Ralina, Krieger Adam, Timlin Homa
Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA.
Rheumatology, Johns Hopkins University School of Medicine, Baltimore, USA.
Cureus. 2025 May 2;17(5):e83337. doi: 10.7759/cureus.83337. eCollection 2025 May.
Current therapeutic options in systemic lupus erythematosus (SLE) vary in effectiveness, and remission may not be achievable in many patients. Unfortunately, although many patients achieve an initial response with conventional immunosuppressant regimens, relapse is common, and current therapies are associated with damaging adverse effects and the risk of infection. Therefore, it is critical to identify safe targets for lupus disease activity, minimizing drug toxicity and preventing damage accrual. We present two cases with disease features of discoid lupus erythematosus (DLE) and lupus nephritis (LN), who were treated safely and successfully with Voclosporin and Anifrolumab, resulting in disease remission without the use of oral steroids.
系统性红斑狼疮（SLE）目前的治疗选择效果各异，许多患者可能无法实现缓解。不幸的是，尽管许多患者对传统免疫抑制方案有初始反应，但复发很常见，而且目前的治疗伴有有害的不良反应和感染风险。因此，确定狼疮疾病活动的安全靶点、将药物毒性降至最低并防止损害累积至关重要。我们介绍了两例具有盘状红斑狼疮（DLE）和狼疮性肾炎（LN）疾病特征的病例，他们使用voclosporin和阿尼鲁单抗进行了安全且成功的治疗，在未使用口服类固醇的情况下实现了疾病缓解。
